# 5-MeO-DiPT
*Source: https://psychonautwiki.org/wiki/5-MeO-DiPT*

## Dosage & Duration

### Oral

**Dosage:**
- Threshold: 3 mg
- Light: 3 - 10 mg
- Common: 10 - 15 mg
- Strong: 15 - 20 mg
- Heavy: 20 mg +

**Duration:**
- Total: 4 - 8 hours
- Onset: 20 - 40 minutes
- After effects: 2 - 6 hours

**5-Methoxy-N,N-diisopropyltryptamine** (also known as **5-MeO-DiPT** , **Foxy** , and **Foxy Methoxy** ) is a novel [psychedelic](https://psychonautwiki.org/wiki/Psychedelic) substance of the [tryptamine](https://psychonautwiki.org/wiki/Tryptamine) class that produces [psychedelic](https://psychonautwiki.org/wiki/Psychedelic) effects when [administered](https://psychonautwiki.org/wiki/Administered) . It is related in structure to [DiPT](https://psychonautwiki.org/wiki/DiPT) and [5-MeO-MiPT](https://psychonautwiki.org/wiki/5-MeO-MiPT) .

The first human trials of 5-MeO-DiPT were undertaken by [Alexander Shulgin](https://psychonautwiki.org/wiki/Alexander_Shulgin) in 1975. who would co-author and publish a paper detailing its synthesis and human psychopharmacology in 1981. A summary of the synthesis and reports of human use is included in Shulgin's 1997 book *[TiHKAL](https://psychonautwiki.org/wiki/TiHKAL)* ("Tryptamines I Have Known And Loved").

Anecdotal reports characterize the effects of this compound as highly [stimulating](https://psychonautwiki.org/wiki/Stimulating) and mildly [entactogenic](https://psychonautwiki.org/wiki/Entactogenic) , lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to [enhance libido](https://psychonautwiki.org/wiki/Increased_libido) and sexual pleasure. Many users note an unpleasant body load accompanies higher dosages. Some users also report sound distortion, which is also noted with the related compound, [DiPT](https://psychonautwiki.org/wiki/DiPT) .

Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-DiPT. It is relatively obscure and has a limited history of human use. It has been sold online as a [research chemical](https://psychonautwiki.org/wiki/Research_chemical) . It is highly advised to use [harm reduction practices](https://psychonautwiki.org/wiki/Harm_reduction_practices) if using this substance.

## Chemistry

5-MeO-DiPT, or 5-methoxy-N,N-diisopropyltryptamine, is a synthetic indole alkaloid molecule of the [tryptamine](https://psychonautwiki.org/wiki/Tryptamine) class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R 3 to an amino group via an ethyl side chain. 5-MeO-DiPT is substituted at R 5 of its indole heterocycle with a methoxy (MeO) functional group CH 3 O−; it also contains two isopropyl chains bound to the terminal amine R N of its tryptamine backbone (DiPT).

5-MeO-DiPT is the N-substituted diisopropyl homolog of [5-MeO-MiPT](https://psychonautwiki.org/wiki/5-MeO-MiPT) .

## Pharmacology

The mechanism that produces the purported hallucinogenic and entheogenic effects of 5-MeO-DiPT is thought to result primarily from 5-HT 2A receptor agonism, although additional mechanisms of action such as monoamine oxidase inhibition (MAOI) may be involved also. The strongest receptor binding affinity for 5-MeO-DiPT is at the 5-HT 1A receptor. However, the role of these interactions and how they result in the [psychedelic](https://psychonautwiki.org/wiki/Psychedelic) experience continues to remain elusive.

5-MeO-DiPT is neurotoxic in rats. </ref>

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Stimulation](https://psychonautwiki.org/wiki/Stimulation)**
- **[Spontaneous physical sensations](https://psychonautwiki.org/wiki/Spontaneous_physical_sensations)**
- **[Bodily pressures](https://psychonautwiki.org/wiki/Bodily_pressures)**
- **[Nausea](https://psychonautwiki.org/wiki/Nausea)**
- **[Abnormal heartbeat](https://psychonautwiki.org/wiki/Abnormal_heartbeat)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Increased heart rate](https://psychonautwiki.org/wiki/Increased_heart_rate)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Increased blood pressure](https://psychonautwiki.org/wiki/Increased_blood_pressure)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Headaches](https://psychonautwiki.org/wiki/Headaches)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Stomach bloating](https://psychonautwiki.org/wiki/Stomach_bloating)** - At higher dosages, this compound can induce severe stomach bloating within those who are susceptible to it. This can be partially to fully mitigated through the use of [antacids](https://en.wikipedia.org/wiki/Antacid) .
- **[Vasoconstriction](https://psychonautwiki.org/wiki/Vasoconstriction)**
- **[Diarrhea](https://psychonautwiki.org/wiki/Diarrhea)**
- **[Dehydration](https://psychonautwiki.org/wiki/Dehydration)**
- **[Pupil dilation](https://psychonautwiki.org/wiki/Pupil_dilation)** ### Visual effects
 
- #### Enhancements
 
- **[Colour enhancement](https://psychonautwiki.org/wiki/Colour_enhancement)**
- **[Pattern recognition enhancement](https://psychonautwiki.org/wiki/Pattern_recognition_enhancement)**
- **[Visual acuity enhancement](https://psychonautwiki.org/wiki/Visual_acuity_enhancement)**
 
#### Distortions
 
- **[Drifting](https://psychonautwiki.org/wiki/Drifting)** *( [melting](https://psychonautwiki.org/wiki/Drifting#Melting) , [breathing](https://psychonautwiki.org/wiki/Drifting#Breathing) , [morphing](https://psychonautwiki.org/wiki/Drifting#Morphing) and [flowing](https://psychonautwiki.org/wiki/Drifting#Flowing) )*
- **[Colour shifting](https://psychonautwiki.org/wiki/Colour_shifting)**
- **[Depth perception distortions](https://psychonautwiki.org/wiki/Depth_perception_distortions)**
- **[Perspective distortions](https://psychonautwiki.org/wiki/Perspective_distortions)**
- **[Symmetrical texture repetition](https://psychonautwiki.org/wiki/Symmetrical_texture_repetition)**
- **[Tracers](https://psychonautwiki.org/wiki/Tracers)**
- **[After images](https://psychonautwiki.org/wiki/After_images)**
- **[Brightness alteration](https://psychonautwiki.org/wiki/Brightness_alteration)**
- **[Diffraction](https://psychonautwiki.org/wiki/Diffraction)**
 
#### Geometry
 
#### Hallucinatory states
 
- **[Transformations](https://psychonautwiki.org/wiki/Transformations)**
- **[Internal hallucination](https://psychonautwiki.org/wiki/Internal_hallucination)** ( *[autonomous entities](https://psychonautwiki.org/wiki/Autonomous_entities)* ; *[settings, sceneries, and landscapes](https://psychonautwiki.org/wiki/Settings,_sceneries,_and_landscapes)* ; *[perspective hallucinations](https://psychonautwiki.org/wiki/Perspective_hallucinations)* and *[scenarios and plots](https://psychonautwiki.org/wiki/Scenarios_and_plots)* ) ### Cognitive effects
 
- - **[Conceptual thinking](https://psychonautwiki.org/wiki/Conceptual_thinking)**
- **[Cognitive euphoria](https://psychonautwiki.org/wiki/Cognitive_euphoria)**
- **[Delusion](https://psychonautwiki.org/wiki/Delusion)**
- **[Emotion enhancement](https://psychonautwiki.org/wiki/Emotion_enhancement)**
- **[Immersion enhancement](https://psychonautwiki.org/wiki/Immersion_enhancement)**
- **[Increased music appreciation](https://psychonautwiki.org/wiki/Increased_music_appreciation)**
- **[Memory suppression](https://psychonautwiki.org/wiki/Memory_suppression)** 
- **[Ego death](https://psychonautwiki.org/wiki/Ego_death)**
- **[Novelty enhancement](https://psychonautwiki.org/wiki/Novelty_enhancement)**
- **[Personal bias suppression](https://psychonautwiki.org/wiki/Personal_bias_suppression)**
- **[Thought loops](https://psychonautwiki.org/wiki/Thought_loops)**
- **[Time distortion](https://psychonautwiki.org/wiki/Time_distortion)**
- **[Unity and interconnectedness](https://psychonautwiki.org/wiki/Unity_and_interconnectedness)** ### Auditory effects
 
- - **[Enhancements](https://psychonautwiki.org/wiki/Auditory_enhancement)**
- **[Distortions](https://psychonautwiki.org/wiki/Auditory_distortion)**
- **[Hallucinations](https://psychonautwiki.org/wiki/Auditory_hallucinations)**
### Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) . Additional experience reports can be found here:

- [Erowid Experience Vaults: 5-MeO-DiPT](https://erowid.org/experiences/subs/exp_5MeODiPT.shtml)

## Toxicity and harm potential

The long-term health effects of recreational 5-MeO-DiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-DiPT is a [research chemical](https://psychonautwiki.org/wiki/Research_chemical) with very little history of human usage. The neurotoxic effects has been studies in rats.

Anecdotal reports suggest that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed). [Independent research](https://www.google.com/) should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this substance.

### Overdose

Excessive doses have caused [nausea](https://psychonautwiki.org/wiki/Nausea) , vomiting, agitation, [decreased blood pressure](https://psychonautwiki.org/wiki/Decreased_blood_pressure) , [pupil dilation](https://psychonautwiki.org/wiki/Pupil_dilation) , [increased heart rate](https://psychonautwiki.org/wiki/Increased_heart_rate) , and hallucinations in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man and another one died 3–4 hours after an apparent rectal overdose. A 24-year-old man also died of this compound being administered into the colon.

### Tolerance and addiction potential

Like other [serotonergic psychedelics](https://psychonautwiki.org/wiki/Serotonergic_psychedelic) , 5-MeO-DiPT is not habit-forming.

Tolerance to the effects of 5-MeO-DiPT builds almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-DiPT presents cross-tolerance with all [psychedelics](https://psychonautwiki.org/wiki/Psychedelic) , meaning that after the consumption of 5-MeO-DiPT all psychedelics will have a reduced effect.

### Dangerous interactions

***Warning:*** *Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).*

*Always conduct independent research (e.g. [Google](https://www.google.com) , [DuckDuckGo](https://www.duckduckgo.com) , [PubMed](https://pubmed.ncbi.nlm.nih.gov/) ) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from [TripSit](https://combo.tripsit.me) .*

- **2C-T-X** - Both classes of compounds can be unpredictable alone.
- **2C-X** - The 5-MeO psychedelics can interact unpredictably to potentiate other psychedelics.
- **Cannabis** - May increase the risk of negative psychological effects such as [anxiety](https://psychonautwiki.org/wiki/Anxiety) , [paranoia](https://psychonautwiki.org/wiki/Paranoia) , and [psychosis](https://psychonautwiki.org/wiki/Psychosis) .
- **DOx** - The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
- **MDMA** - Some of the 5-MeO tryptamines are a bit unpredictable and should be mixed with MDMA with care.
- **Mescaline** - The 5-MeO class of tryptamines can be unpredictable in their interactions.
- **NBOMe** - The 5-MeO class of tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. This combination is best avoided.
- **Amphetamines** - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
- **Cocaine** - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
- **DXM** - Little information exists about this combination.
- **Tramadol** - Increased risk of [serotonin syndrome](https://psychonautwiki.org/wiki/Serotonin_syndrome) .
- **aMT** - Increased risk of [serotonin syndrome](https://psychonautwiki.org/wiki/Serotonin_syndrome) .
- **MAOIs** - Increased risk of [serotonin syndrome](https://psychonautwiki.org/wiki/Serotonin_syndrome) .
- **PCP** - Little information exists about this combination. May increase risk of psychosis and excessive stimulation.

5-MeO-DiPT is a monoaminergic reuptake inhibitor (MRI). 5-MeO-DiPT and [MAOIs](https://psychonautwiki.org/wiki/MAOIs) are a potentially dangerous combination. It is likely that MAOIs could increase the effects of 5-MeO-DiPT unpredictably. Taking this chemical while on prescription MAOIs is strongly discouraged.

## Legal status

- **Brazil** : Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
- **China** : 5-MeO-DiPT is illegal in China.
- **Denmark** : 5-MeO-DiPT is illegal in Denmark. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Germany** : 5-MeO-DiPT is controlled under Anlage I BtMG ( *Narcotics Act, Schedule I* ) as of October 10, 2000. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
- **Greece** : 5-MeO-DiPT is illegal in Greece. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Japan** : 5-MeO-DiPT is illegal in Japan. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Latvia** : 5-MeO-DiPT is illegal in Latvia. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **New Zealand** : 5-MeO-DiPT can be considered an analogue of DMT, which makes it a Class C controlled drug in New Zealand.
- **Singapore** : 5-MeO-DiPT is illegal in Singapore. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Sweden** : 5-MeO-DiPT is illegal in Sweden.
- **Switzerland** : 5-MeO-DiPT is a controlled substance specifically named under Verzeichnis E.
- **United Kingdom** : 5-MeO-DiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-DiPT, which is a Class A drug as a result of the tryptamine catch-all clause.
- **United States** : 5-MeO-DiPT is a Schedule 1 controlled substance. On April 4, 2003, the United States DEA added both 5-MeO-DiPT and αMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004.

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use)
- [Research chemical](https://psychonautwiki.org/wiki/Research_chemical)
- [Tryptamine](https://psychonautwiki.org/wiki/Tryptamine)
- [5-MeO-MiPT](https://psychonautwiki.org/wiki/5-MeO-MiPT)
- [4-AcO-DiPT](https://psychonautwiki.org/wiki/4-AcO-DiPT)
- [DiPT](https://psychonautwiki.org/wiki/DiPT)

## External links

- [5-MeO-DiPT (Wikipedia)](https://en.wikipedia.org/wiki/5-Methoxy-diisopropyltryptamine)
- [5-MeO-DiPT (Erowid Vault)](https://erowid.org/chemicals/5meo_dipt/5meo_dipt.shtml)
- [5-MeO-DiPT (TiHKAL / Isomer Design)](http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=37)

### Discussion

- [The Big & Dandy 5-MeO-DiPT Thread (Bluelight)](https://www.bluelight.org/xf/threads/57817)

## References
1. ↑ [Alexander Shulgin](https://psychonautwiki.org/wiki/Alexander_Shulgin)(1976).[Pharmacology Notes I (The Shulgin Lab Books)](https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf)(PDF). Lafayette, CA: Erowid. p. 176.
2. ↑ [Shulgin, A. T.](https://psychonautwiki.org/wiki/Alexander_Shulgin); Carter, M. F. (1980). "N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity".*Communications in psychopharmacology*.**4**(5): 363–369.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0145-5699](//www.worldcat.org/issn/0145-5699).[OCLC](http://en.wikipedia.org/wiki/OCLC)[3012956](//www.worldcat.org/oclc/3012956).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[6949674](//www.ncbi.nlm.nih.gov/pubmed/6949674).
3. ↑ [Shulgin, Alexander](https://psychonautwiki.org/wiki/Alexander_Shulgin); Shulgin, Ann (1997).*[TiHKAL: The Continuation](https://psychonautwiki.org/wiki/TiHKAL)*. United States: Transform Press.[ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number)[0-9630096-9-9](http://en.wikipedia.org/wiki/Special:BookSources/0-9630096-9-9).[OCLC](http://en.wikipedia.org/wiki/OCLC)[38503252](//www.worldcat.org/oclc/38503252).
4. ↑ Nagai, F.; Nonaka, R.; Satoh, K.; Kamimura, H. (2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain".*European Journal of Pharmacology*.**559**(2–3): 132–137.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.ejphar.2006.11.075](//doi.org/10.1016%2Fj.ejphar.2006.11.075).[eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN)[1879-0712](//www.worldcat.org/issn/1879-0712).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0014-2999](//www.worldcat.org/issn/0014-2999).[OCLC](http://en.wikipedia.org/wiki/OCLC)[01568459](//www.worldcat.org/oclc/01568459).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[17223101](//www.ncbi.nlm.nih.gov/pubmed/17223101).
5. ↑ Ray, T. S. (2 February 2010). Manzoni, O. J., ed.["Psychedelics and the Human Receptorome"](https://dx.plos.org/10.1371/journal.pone.0009019).*PLoS ONE*.**5**(2): e9019.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1371/journal.pone.0009019](//doi.org/10.1371%2Fjournal.pone.0009019).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1932-6203](//www.worldcat.org/issn/1932-6203).
6. ↑ 6.0 6.1 Noworyta-Sokołowska, K.; Kamińska, K.; Kreiner, G.; Rogóż, Z.; Gołembiowska, K. (2016).["Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats"](//www.ncbi.nlm.nih.gov/pmc/articles/PMC5047954).*Neurotoxicity Research*.**30**(4): 606–619.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/s12640-016-9654-0](//doi.org/10.1007%2Fs12640-016-9654-0).[eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN)[1476-3524](//www.worldcat.org/issn/1476-3524).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1029-8428](//www.worldcat.org/issn/1029-8428).[OCLC](http://en.wikipedia.org/wiki/OCLC)[50166444](//www.worldcat.org/oclc/50166444).[PMC](http://en.wikipedia.org/wiki/PubMed_Central)[5047954](//www.ncbi.nlm.nih.gov/pmc/articles/PMC5047954).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[27461536](//www.ncbi.nlm.nih.gov/pubmed/27461536).
7. ↑ Randall C. Baselt (2008).*Disposition of Toxic Drugs and Chemicals in Man*(8th ed.). Foster City, CA: Biomedical Publications. pp. 975–976.[ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number)[978-0-9626523-7-0](http://en.wikipedia.org/wiki/Special:BookSources/978-0-9626523-7-0).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0009-9147](//www.worldcat.org/issn/0009-9147).
8. ↑ Tayebati, S. K.; Tomassoni, D.; Nwankwo, I. E.; Di Stefano, A.; Sozio, P.; Cerasa, L. S.; Amenta, F. (2013). "Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain".*Drug Targets - CNS & Neurological Disorders*.**12**(1): 94–103.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2174/1871527311312010015](//doi.org/10.2174%2F1871527311312010015).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1568-007X](//www.worldcat.org/issn/1568-007X).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[23244432](//www.ncbi.nlm.nih.gov/pubmed/23244432).
9. ↑ Trabucchi, M.; Govoni, S.; Battaini, F. (1986). "Changes in the interaction between CNS cholinergic and dopaminergic neurons induced by L-alpha-glycerylphosphorylcholine, a cholinomimetic drug".*Il Farmaco, Edizione Scientifica*.**41**(4): 325–334.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0430-0920](//www.worldcat.org/issn/0430-0920).[OCLC](http://en.wikipedia.org/wiki/OCLC)[1064491979](//www.worldcat.org/oclc/1064491979).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[3709792](//www.ncbi.nlm.nih.gov/pubmed/3709792).
10. ↑ ["RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016"](http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7)(in Portuguese). Agência Nacional de Vigilância Sanitária (Anvisa) [National Sanitary Surveillance Agency]. December 5, 2016. Retrieved January 8, 2020.
11. ↑ ["关于印发《非药用类麻醉药品和精神药品列管办法》的通知"](https://web.archive.org/web/20170906191704/http://www.sfda.gov.cn/WS01/CL0056/130753.html)(in Chinese). 国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]. September 27, 2015. Archived from[the original](http://www.sfda.gov.cn/WS01/CL0056/130753.html)on September 6, 2017. Retrieved August 19, 2020.
12. ↑ ["Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I"](https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html)(in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
13. ↑ ["Vierzehnte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften"](https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl100s1414b.pdf%27%5D#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl100s1414b.pdf%27%5D__1576702069328).*Bundesgesetzblatt Jahrgang 2000 Teil I Nr. 44*(in German). Bundesanzeiger Verlag (published September 30, 2000). September 27, 2000. pp. 1414–1415.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0341-1095](//www.worldcat.org/issn/0341-1095). Retrieved December 18, 2019.
14. ↑ ["Gesetz über den Verkehr mit Betäubungsmitteln: § 29"](https://www.gesetze-im-internet.de/btmg_1981/__29.html)(in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
15. ↑ ["Schedule 1: Class A controlled drugs"](http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576).*Misuse of Drugs Act 1975*. Parliamentary Counsel Office (PCO). Retrieved September 19, 2020.
16. ↑ ["Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor"](http://www.notisum.se/rnp/sls/sfs/20040696.pdf)(PDF)(in Swedish) (published September 7, 2004). August 19, 2004. SFS 2004:696.
17. ↑ ["Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html)(in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
18. ↑ ["Schedule 2: Part I: Class A Drugs"](http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I).*"Misuse of Drugs Act 1971"*. UK Government. Retrieved August 20, 2020.
19. ↑ [Schedules of Controlled Substances: Placement of Alpha- Methyltryptamine and 5-Methoxy-N,N-Diisopropyltryptamine Into Schedule I](https://www.deadiversion.usdoj.gov/fed_regs/rules/2004/fr0929.htm)NewPP limit report Cached time: 20251218075130 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.046 seconds CPU time usage: 0.378 seconds Real time usage: 0.796 seconds Preprocessor visited node count: 1919/1000000 Post‐expand include size: 123513/2097152 bytes Template argument size: 13029/2097152 bytes Highest expansion depth: 22/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 27185/5000000 bytes Lua time usage: 0.320/7 seconds Lua virtual size: 8.6 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 650.045 1 -total 21.30% 138.459 6 Template:Cite_journal 18.20% 118.322 1 Template:Effects/base 17.66% 114.797 1 Template:Effect_list 17.19% 111.757 3 Template:Cite_book 17.10% 111.132 2 Template:Effect_column 14.83% 96.391 1 Template:Effects/physical 14.73% 95.766 9 Template:Cite_web 14.35% 93.298 4 Template:Effect_panel 13.74% 89.333 9 Template:Citation_needed